Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-29

Engineering of the porcine genome for xenotransplantation studies in primates: a step towards clinical application

Objetivo

The ultimate goal of our Consortium is to generate the necessary data to allow xenotransplantation to progress towards its initial clinical phase. The data generated during this project will encompass both efficacy and safety aspects of xeno-transplantation. Tools that will be used to reach this ambitious objective encompass state-of-the-art biomolecular technologies and in vivo models. XENOME aims to produce a "super-engineered" pig, i.e. a pig with a newly generated genotype that will improve the efficacy and safety profile of xenotransplantation. Assessments of efficacy will first take advantage of existing pig lines expressing human complement regulators, thrombomodulin (TM) and knock-out for a-Gal transferase. Using the most suitable background, further engineering will eliminate one or more PERV sequences. Additional transgenes, such as HO-1, CD39 and other molecules able to control immune responses, endothelial cell activation and subsequent microangiopathy, will be added.

The ultimate pig strain will thus combine the already available background with novel molecules exhibiting anti-inflammatory, anticoagulant and immunosuppressive properties. In addition, an effective immuno-suppression regimen will be defined and new pharmaceutical agents will be tested. A strong safety framework will also be established that may allow, at some stage, progression of xenotransplantation into the clinic. This will involve development of technologies enabling the timely diagnosis of infection, design of a safety plan for an efficacious containment of an untoward infectious event, breeding of a herd of "clean" source pigs, inactivation of PERV sequences and provide safety-related data deriving from long-term in vivo studies in primate xenograft recipients. Finally, the project will also provide a strong ethical, social (especially regarding public communication) and regulatory framework for xenotransplantation research (and possibly clinical application).

Ámbito científico

Programa(s)

Tema(s)

Convocatoria de propuestas

FP6-2005-LIFESCIHEALTH-6
Consulte otros proyectos de esta convocatoria

Régimen de financiación

IP - Integrated Project

Coordinador

AZIENDA OSPEDALIERA DI PADOVA
Aportación de la UE
Sin datos
Dirección
Via Giustiniani 2
PADOVA
Italia

Ver en el mapa
Enlaces
Coste total
Sin datos

Participantes (25)

Compartir esta página

Descargar

Última actualización: 2 Mayo 2012

Mi folleto

Permalink: https://cordis.europa.eu/project/id/37377/es

European Union, 2024